Related Experiment Video
Updated: Mar 22, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Antiretroviral therapy during pregnancy and risk of preterm birth
Louise-Helene Gagnon1, Jay MacGillivray2, Marcelo L Urquia3
1Department of Obstetrics and Gynecology, University of Toronto, Canada.
Insights
Antiretroviral therapy (ART) in pregnancy may increase risks of preterm birth, low birth weight, and small for gestational age infants. However, adjusted analyses in this study lacked statistical significance due to limited power, suggesting a need for larger research.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Neonatal Health
Background:
- Antiretroviral therapy (ART) use during pregnancy, particularly protease inhibitor (PI) regimens, is linked to adverse infant outcomes like preterm birth (PTB), low birth weight (LBW), and small for gestational age (SGA).
- Existing literature presents conflicting data on the magnitude of these risks, potentially due to demographic factors and confounding variables such as maternal HIV status and immune suppression levels.
Purpose of the Study:
- To evaluate the risk of PTB in HIV-positive pregnant women on ART compared to HIV-negative pregnant women.
- To compare the risks of LBW and SGA infants between these two groups.
- To specifically assess PTB, LBW, and SGA risks in women on PI-based ART regimens versus controls.
Main Methods:
- A retrospective matched cohort study involving 384 women from 2007-2012.
- Comparison of adverse infant outcomes between HIV-positive women on ART and HIV-negative women.
- Utilized univariate and multivariable logistic regression, adjusting for confounding factors like race.
Main Results:
- Unadjusted analyses indicated over a two-fold increase in PTB, LBW, and SGA rates for HIV-positive women on ART.
- After adjusting for race, the increased odds ratios for PTB, LBW, and SGA were no longer statistically significant.
- The study was underpowered to detect smaller differences, with adjusted odds ratios for PTB (1.4), LBW (1.9), and SGA (1.8) not reaching statistical significance.
Conclusions:
- Preliminary findings suggest a potential increase in PTB, LBW, and SGA associated with ART use in pregnancy.
- Adjusted results were not statistically significant due to insufficient study power.
- A larger, prospective study is recommended to confirm these preliminary findings and explore the associations further.
Background:
Antiretroviral therapy use in pregnancy, and specifically regimens containing protease inhibitors (PIs), has been associated with adverse infant outcomes including preterm birth (PTB), low birth weight (LBW) and small for gestational age (SGA) infants. However, there are conflicting results in the literature with respect to the degree of risk. These results may be related to demographic factors and confounding of maternal HIV infection and degree of immune suppression.
Objective:
The primary objective of our study was to assess the risk of PTB in HIV-positive pregnant women on ART compared to HIV-negative pregnant women. Secondary objectives included: comparing the risks of LBW and SGA infants in HIV-positive women on ART to HIV-negative pregnant women; comparing the risks of PTB, LBW and SGA in HIV-positive women on PI-based regimens compared to HIV-negative women.
Methods:
A retrospective matched cohort study of 384 women was conducted between 2007 and 2012 comparing outcomes of HIV-positive women on ART to HIV-negative women. Univariate and multivariable logistic regression models were used, adjusting for potential confounding factors, to compare the two groups on adverse infant outcomes.
Results:
Unadjusted odds ratios revealed a >2-fold increase in rates: PTB OR 2.6 [95% CI 1.3-5.1]; LBW OR 2.9 [95% CI 1.4-6.3]; SGA OR 2.5 [95% CI 1.3-4.7]. Once odds ratios were adjusted to account for race (p<0.01), our results were no longer statistically significant as this study was underpowered to detect smaller differences: PTB aOR 1.4 [95% CI 0.5-3.6]; LBW OR 1.9 [95% CI 0.6-5.5]; SGA OR 1.8 [95% CI 0.8-4.6].
Conclusion:
Our preliminary results show an increase in PTB, LBW and SGA but due to lack of power, our adjusted results are not statistically significant. A larger prospective follow-up study is needed to further explore these findings in this population.
Related Concept Videos
Retrovirus Life Cycles
Teratogenicity
Pharmacokinetics in Pediatric Patients: Drug Excretion
Rh Blood Group
Development of the Oral Microbiota
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

